ALLEGRO MICROSYSTEMS INC
For the period ended Mar 28, 2025. Filed May 22, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed May 22, 2025
ALGM$30.70-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
| Fiscal Year Ended | |||
|---|---|---|---|
| March 28,2025 | March 29,2024 | March 31,2023 | |
| Cash flows from operating activities: | |||
| Net (loss) income | $(72,763) | $152,888 | $187,494 |
| Adjustments to reconcile net (loss) income to net cash provided by operating activities: | |||
| Depreciation and amortization | 64,502 | 71,382 | 50,808 |
| Amortization of deferred financing costs | 2,513 | 527 | 99 |
| Deferred income taxes | (16,301) | (18,613) | (40,116) |
| Stock-based compensation | 41,868 | 42,457 | 61,798 |
| Loss on change in fair value of forward repurchase contract | 34,752 | — | — |
| Change in fair value of contingent consideration | — | — | (2,800) |
| Impairment of long-lived assets | — | 13,218 | — |
| Provisions for inventory and expected credit losses | 9,216 | 10,286 | (1,438) |
| Change in fair value of marketable securities | — | 3,579 | (7,471) |
| Other non-cash reconciling items | 6,984 | 70 | 285 |
| Changes in operating assets and liabilities: | |||
| Trade accounts receivable | 33,081 | (7,964) | (12,484) |
| Accounts receivable - other | 155 | (1,035) | 2,226 |
| Inventories | (30,160) | (15,848) | (75,150) |
| Prepaid expenses and other assets | (4,756) | (40,231) | (23,263) |
| Trade accounts payable | 4,044 | (12,653) | 11,958 |
| Due to and from related party | 5,115 | 5,231 | 18,326 |
| Accrued expenses and other current and long-term liabilities | (16,337) | (21,579) | 22,934 |
| Net cash provided by operating activities | 61,913 | 181,715 | 193,206 |
| Cash flows from investing activities: | |||
| Purchases of property, plant and equipment | (39,955) | (124,772) | (79,775) |
| Purchases of intangible assets | (1,180) | — | — |
| Acquisition of business, net of cash acquired and working capital adjustment | 319 | (408,119) | (19,921) |
| Sales in marketable securities | — | 16,175 | — |
| Net cash used in investing activities | (40,816) | (516,716) | (99,696) |
| Cash flows from financing activities: | |||
| Loans made to related party | — | — | (7,500) |
| Borrowings of 2023 Term Loan Facility, net of deferred financing costs | — | 245,452 | — |
| Repayment of 2020 Term Loan Facility | — | (25,000) | — |
| Net proceeds from Refinanced 2023 Term Loan Facility | 193,081 | — | — |
| Repayment of 2023 Term Loan Facility | (105,000) | (625) | — |
| Repayments of other debt | — | (842) | — |
| Finance lease payments | (1,201) | (142) | — |
| Receipts on related party notes receivable | 1,875 | 3,750 | 2,812 |
| Payments for taxes related to net share settlement of equity awards | (16,238) | (25,900) | (18,061) |
| Proceeds from issuance of common stock under employee purchase plan | 3,511 | 3,635 | 2,793 |
| Repurchases of common stock | (853,921) | — | — |
| Net proceeds from issuance of common stock | 665,850 | — | — |
| Dividends paid to non-controlling interest | (19) | — | (42) |
| Payments of debt issuance costs | — | (1,450) | — |
| Net cash (used in) provided by financing activities | (112,062) | 198,878 | (19,998) |
| Effect of exchange rate changes on cash and cash equivalents and restricted cash | (89) | (421) | (4,606) |
| Net (decrease) increase in cash and cash equivalents and restricted cash | (91,054) | (136,544) | 68,906 |
| Cash and cash equivalents and restricted cash at beginning of period | 222,161 | 358,705 | 289,799 |
| Cash and cash equivalents and restricted cash at end of period: | $131,107 | $222,161 | $358,705 |
| Reconciliation of cash and cash equivalents and restricted cash: | |||
| Cash and cash equivalents at beginning of period | $212,143 | $351,576 | $282,383 |
| Restricted cash at beginning of period | 10,018 | 7,129 | 7,416 |
| Cash and cash equivalents and restricted cash at beginning of period | $222,161 | $358,705 | $289,799 |
| Cash and cash equivalents at end of period | 121,334 | 212,143 | 351,576 |
| Restricted cash at end of period | 9,773 | 10,018 | 7,129 |
| Cash and cash equivalents and restricted cash at end of period | $131,107 | $222,161 | $358,705 |
Consolidated Statements of Cash Flows - continued
| Fiscal Year Ended | |||
|---|---|---|---|
| March 28,2025 | March 29,2024 | March 31,2023 | |
| Supplemental disclosures of cash flow information: | |||
| Cash paid for interest | $21,959 | $10,153 | $1,923 |
| Cash paid for income taxes, net of refunds | $11,639 | $89,927 | $58,209 |
| Non-cash transactions: | |||
| Property, plant and equipment purchases included in trade accounts payable and accrued expenses | $(4,463) | $(4,157) | $(16,369) |
| Right-of-use assets obtained in exchange for lease liabilities | $6,999 | $10,450 | $4,870 |
| Assets held for sale transferred from property, plant and equipment, net | $16,508 | $— | $— |
Notes to Consolidated Financial Statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.